Summary statement: Novel agents in the treatment of lung cancer: Advances in epidermal growth factor receptor-targeted agents

Clinical Cancer Research

Volumn 12, Issue 14, 2006, Pages

  Lynch, Thomas J ^a   Adjei, Alex A ^c   Bunn Jr , Paul A ^d   Eisen, Tim G ^e   Engelman, Jeffrey ^b   Goss, Glenwood D ^f   Haber, Daniel A ^a   Heymach, John V ^g   Jänne, Pasi A ^b   Johnson, Bruce E ^b   Johnson, David H ^h   Lilenbaum, Rogerio C ⁱ   Meyerson, Matthew ^b   Sandler, Alan B ^h   Sequist, Lecia V ^a   Settleman, Jeffrey ^a   Wong, Kwok Kin ^b   Hart, Carol S ^j  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ Mount Sinai Cancer Center   (United States)

^j InforMEDical   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; TAXANE DERIVATIVE; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; DRUG SENSITIVITY; HUMAN; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746880651     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1005     Document Type: Conference Paper

References (2)

1. Kris MG, Natale, RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-58.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2191-3.